The right immune-modulation at the right time: thymosin α1 for prevention of severe COVID-19 in cancer patients
Abstract
We presented the rationale for the use of thymosin α1 as prophylaxis of severe COVID-19 in cancer patients undergoing active treatment, constituting the background for the PROTHYMOS study, a prospective, multicenter, open-label, Phase II randomized study, currently in its start-up phase (Eudract no. 2020-006020-13). We aim to offer new hope for this incurable disease, especially to frail patient population, such as patients with cancer. The...
Paper Details
Title
The right immune-modulation at the right time: thymosin α1 for prevention of severe COVID-19 in cancer patients
Published Date
Mar 1, 2021
Journal
Volume
17
Issue
9
Pages
1097 - 1104
Citation AnalysisPro
You’ll need to upgrade your plan to Pro
Looking to understand the true influence of a researcher’s work across journals & affiliations?
- Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
- Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.
Notes
History